Bayhealth among elite group receiving early access to new stent technology Bayhealth Hospital, Kent Campus was chosen as one of a select group of hospitals nationwide — only 50 in the U.S. and five on the entire East Coast — to receive early access to a new FDA approved stent treatment. Produced by Boston Scientific, the Eluvia stent system is an innovative technology that gradually releases a medication to the main arteries supplying blood to the legs and other extremities. It is designed to help those with peripheral vascular disease (PVD), a common circulatory condition caused by a buildup of fatty deposits in the arteries that restricts blood flow. PVD is estimated to affect one in every 20 Americans, causing pain, ulceration and in the most severe cases, a need for leg amputation. When left untreated, it can increase a person’s risk for heart attack and stroke. During clinical trials, the Eluvia stent system showed superior results in treating blockages in the legs and relieving symptoms compared to similar products on the market. Because of the muscles and bones in the legs, blockages in that location are traditionally harder to treat with stenting than are those in the heart.
THE FACT THAT BAYHEALTH WAS CHOSEN IN THE INITIAL LAUNCH, AS ONE OF ONLY A HANDFUL OF EAST COAST HOSPITALS TO RECEIVE THE PRODUCT, IS QUITE AN HONOR. — JOHN SHUCK, MD
Bayhealth has had successful results in using the new medication-coated stent to benefit numerous patients in the area. “We were thrilled to get early access to this improved leg stent technology with a proven track record in helping patients suffering from PVD,” said Medical Director of the Cardiovascular Laboratory John Shuck, MD, of Bayhealth Cardiology Consultants. “The fact that Bayhealth was chosen in the initial launch, as one of only a handful of East Coast hospitals to receive the product, is quite an honor.”
8
